NASDAQ:FOLD Amicus Therapeutics (FOLD) Stock Price, News & Analysis $9.41 +0.05 (+0.53%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Amicus Therapeutics Stock (NASDAQ:FOLD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Amicus Therapeutics alerts:Sign Up Key Stats Today's Range$9.21▼$9.4650-Day Range$9.02▼$10.4952-Week Range$8.78▼$14.03Volume1.61 million shsAverage Volume1.84 million shsMarket Capitalization$2.81 billionP/E RatioN/ADividend YieldN/APrice Target$16.88Consensus RatingModerate Buy Company OverviewAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Read More… Amicus Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks88th Percentile Overall ScoreFOLD MarketRank™: Amicus Therapeutics scored higher than 88% of companies evaluated by MarketBeat, and ranked 116th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAmicus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAmicus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amicus Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Amicus Therapeutics are expected to grow in the coming year, from ($0.04) to $0.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amicus Therapeutics is -27.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amicus Therapeutics is -27.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAmicus Therapeutics has a PEG Ratio of 1.25. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmicus Therapeutics has a P/B Ratio of 17.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amicus Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.48% of the outstanding shares of Amicus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAmicus Therapeutics has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Amicus Therapeutics has recently decreased by 1.22%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmicus Therapeutics does not currently pay a dividend.Dividend GrowthAmicus Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.28 Percentage of Shares Shorted6.48% of the outstanding shares of Amicus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAmicus Therapeutics has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Amicus Therapeutics has recently decreased by 1.22%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment0.25 News SentimentAmicus Therapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Amicus Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for FOLD on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows4 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $259,862.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Amicus Therapeutics is held by insiders.Read more about Amicus Therapeutics' insider trading history. Receive FOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FOLD Stock News HeadlinesAmicus Therapeutics' (FOLD) "Overweight" Rating Reaffirmed at Cantor FitzgeraldJanuary 18 at 2:43 AM | americanbankingnews.comAmicus Therapeutics, Inc. (FOLD): The Biotech Stock with Biggest Upside PotentialJanuary 17 at 12:20 PM | insidermonkey.comWall St turns to THIS catalyst after Trump’s inaugurationWall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger than his inauguration. As soon as January 29th…January 20, 2025 | Timothy Sykes (Ad)Positive Outlook for Amicus Therapeutics: Strong Galafold Performance and Strategic Expansion Plans for Future GrowthJanuary 15, 2025 | markets.businessinsider.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of "Moderate Buy" by BrokeragesJanuary 15, 2025 | americanbankingnews.comAmicus Therapeutics: Strong Revenue Performance and Positive Outlook Justify Buy RatingJanuary 14, 2025 | markets.businessinsider.comNCLA Amicus Brief Asks Supreme Court to Keep Unlawful Corporate Transparency Act EnjoinedJanuary 13, 2025 | globenewswire.comAmicus reports preliminary FY24 revenue of $528M, consensus $526.12MJanuary 13, 2025 | markets.businessinsider.comSee More Headlines FOLD Stock Analysis - Frequently Asked Questions How have FOLD shares performed this year? Amicus Therapeutics' stock was trading at $9.42 on January 1st, 2025. Since then, FOLD stock has decreased by 0.1% and is now trading at $9.41. View the best growth stocks for 2025 here. How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). The firm's revenue was up 34.0% on a year-over-year basis. Who are Amicus Therapeutics' major shareholders? Top institutional investors of Amicus Therapeutics include Assenagon Asset Management S.A. (0.16%), Diversified Trust Co (0.03%), Inspire Investing LLC (0.01%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, David Michael Clark, Samantha Prout, Michael Raab and Margaret G Mcglynn. View institutional ownership trends. How do I buy shares of Amicus Therapeutics? Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amicus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amicus Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Walt Disney (DIS), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings8/08/2024Today1/20/2025Next Earnings (Estimated)2/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:FOLD CUSIP03152W10 CIK1178879 Webwww.amicusrx.com Phone(215) 921-7600Fax609-662-2001Employees480Year Founded2002Price Target and Rating Average Stock Price Target$16.88 High Stock Price Target$21.00 Low Stock Price Target$12.00 Potential Upside/Downside+79.3%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth1.25Net Income$-151,580,000.00 Net Margins-21.21% Pretax Margin-13.85% Return on Equity-15.97% Return on Assets-3.17% Debt Debt-to-Equity Ratio2.18 Current Ratio3.15 Quick Ratio2.42 Sales & Book Value Annual Sales$399.36 million Price / Sales7.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book17.11Miscellaneous Outstanding Shares298,810,000Free Float292,232,000Market Cap$2.81 billion OptionableOptionable Beta0.62 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:FOLD) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.